TherapeuticsMD Inc risk profile
69 Stretched several inputs deteriorating together
Measured 21 October 2026 from TXMD's filed statements. Recomputed nightly.
69 (Stretched), driven by Competitive position at 100, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 74 | Stretched | Volatile | One-year price volatility — 74.3% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | Reads operating_cashflow, capital_expenditure, free_cashflow, net_income and revenue. No reading is stored for this company. | |||
| Leverage and coverage | 6 | Contained | Easing | Current ratio — 3.02x |
| Competitive position | 100 | Acute | Stable | Operating-margin gap against peers — -40.3 percentage points |
| Concentration | 54 | Elevated | Stable | Geographic concentration — 3,516 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for TherapeuticsMD Inc